DRG Market Assessment reports

Pulmonary hypertension (PH) is a high-burden condition with significant unmet needs across the major markets. Despite its small patient pool, the commercial potential for PH therapies is…

Resistant hypertension (RHTN) has become a critical focus within the cardiovascular market because a substantial proportion of patients remain uncontrolled despite multidrug therapy, with…

Hypertension remains the most prevalent and clinically significant modifiable risk factor for cardiovascular disease. Treatment typically begins with firstline therapies centered around…

Pulmonary arterial hypertension (PAH) treatment in the United States is undergoing notable shifts as physicians increasingly adopt guidelinealigned early combination therapy, driving steady use of…

Clarivate Epidemiology’s coverage of hypertension includes epidemiological estimates for key patient populations across 45 countries worldwide. We report the prevalence of hypertension for each…

Pulmonary hypertension (PH) is a devastating disease characterized by high blood pressure that affects the pulmonary arteries and the right side of the heart leading to substantial morbidity and…

Pulmonary arterial hypertension (PAH) is a rare and life-threatening disorder characterized by high blood pressure in the arteries of the lungs. The progressive condition is associated with…

Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the rarity of PH, the potential commercial opportunities for drugs approved for…

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder characterized by high blood pressure in the arteries of the lungs. It is a progressive condition marked by considerable…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Pulmonary hypertension disease patient populations, covering 171…

Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of PH…

Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed prevalence of…